Shots: The approval is based on P-III HAWK (NCT02307682) & HARRIER (NCT02434328) studies involves assessing of Beovu (intravitreal injection), 6mg (HAWK and HARRIER) & 3mg (HAWK) vs Aflibercept (2mg) in […]readmore
Tags : Novartis
1. Arbutus to Discontinue its P-Ia/Ib Clinical Study of AB-506 to Treat Patients with Chronic Hepatitis B Published: Oct 03, 2019 | Tags: Arbutus, Discontinue, P-Ia/Ib, Clinical Study, AB-506, Chronic Hepatitis […]readmore
Shots: Novartis to launch AI innovation lab with Microsoft as its strategic AI and data-science partner to transform the discovery, development & commercialization of medicines by leveraging AI & data […]readmore
Biopharma acquisition activity in 2018 shows a significant increase over the previous year. Takeda proved to be on top with the acquisition of Shire among the top 20 acquisitions with […]readmore
1.Boehringer Ingelheim Enters into an Agreement with Inflammasome Therapeutics to Co-Develop Therapies for Retinal Diseases Published: Sept 20, 2019 | Tags: Boehringer Ingelheim, Agreement, Inflammasome Therapeutics, Co-Develop, Therapies, Retinal Disease 2. […]readmore
Shots: The reimbursement of Kisqali is a testament to the ongoing need for public access to the treatment. The Canadian Province, Quebec will reimburse Kisqali + Letrozole under the public […]readmore
Shots: The P-IV VERIFY study involves assessing of Galvus (50mg, bid) + Metformin (1000–2000 mg, qd) vs SOC monothx. approach with metformin initiated in treatment naïve patients (n=2001) in a […]readmore
1.Roche’s Tecentriq + Chemotherapy Receives EC’s Approval as 1L Treatment for Extensive Stage Small Cell Lung Cancer Published: Sept 06, 2019 | Tags: Roche, Tecentriq, Chemotherapy, Receives, EC, Approval, Initial Treatment, […]readmore
Pharma
Regulatory
Novartis’s Capmatinib (INC280) Receives the US FDA’s Breakthrough Therapy Designation
Shots: The US FDA’s BT designation is based on GEOMETRY mono-1 study involves assessing of Capmatinib and the results were also updated in American Society of Clinical Oncology The BT […]readmore
Shots: Novartis to get an option to acquire IFM Due (a subsidiary of IFM Therapeutics) in exchange of funding for research & development of cGAS/STING program. Post exercising of option, […]readmore